UroGen Pharma Ltd.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

URGN$25.32-3.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited; in thousands, except share and per share amounts)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,
	2025	2024	2025	2024
Revenue	$24,215	$21,848	$44,469	$40,629
Cost of revenue	3,550	2,229	5,880	3,957
Gross profit	20,665	19,619	38,589	36,672
Operating expenses:
Research and development expenses	18,914	15,402	38,785	30,896
Selling, general and administrative expenses	43,199	30,056	78,166	57,355
Operating loss	(41,448)	(25,839)	(78,362)	(51,579)
Financing on prepaid forward obligation	(4,644)	(5,773)	(9,227)	(11,433)
Interest expense on long-term debt	(4,132)	(3,461)	(8,200)	(5,908)
Interest and other income, net	1,299	1,708	3,413	3,323
Loss before income taxes	(48,925)	(33,365)	(92,376)	(65,597)
Income tax expense	(1,015)	(38)	(1,407)	(92)
Net Loss	$(49,940)	$(33,403)	$(93,783)	$(65,689)
Statements of Comprehensive Loss
Net loss	$(49,940)	$(33,403)	$(93,783)	$(65,689)
Other comprehensive loss
Unrealized income (loss) on investments	(8)	6	(50)	(43)
Comprehensive Loss	$(49,948)	$(33,397)	$(93,833)	$(65,732)
Net loss per ordinary share - basic and diluted	$(1.05)	$(0.82)	$(1.97)	$(1.69)
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share	47,739,816	40,501,315	47,582,610	38,785,924

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.